These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2358293)

  • 1. Acromegaly. Proceedings of the Symposium on Somatostatin Analogues--Peptide Therapy in Action. January 9th, 1989, London.
    Horm Res; 1990; 33 Suppl 1():1-36. PubMed ID: 2358293
    [No Abstract]   [Full Text] [Related]  

  • 2. Gastro-entero-pancreatic tumours. Proceedings of Somatostatin Analogues--Peptide Therapy in Action Symposium. January 9th, 1989, London.
    Digestion; 1990; 45 Suppl 1():1-63. PubMed ID: 2335265
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives in gastroenterology. Proceedings of Somatostatin Analogues--Peptide Therapy in Action Symposium. January 10th, 1989, London.
    Digestion; 1990; 45 Suppl 1():45-87. PubMed ID: 2335267
    [No Abstract]   [Full Text] [Related]  

  • 4. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary therapy for acromegaly with somatostatin analogs and a discussion of novel peptide analogs.
    Kleinberg DL
    Rev Endocr Metab Disord; 2005 Jan; 6(1):29-37. PubMed ID: 15711912
    [No Abstract]   [Full Text] [Related]  

  • 6. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
    Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
    Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of acromegaly with octreotide, a synthetic analog of somatostatin with extended action].
    Arosio M; Bazzoni N; Faglia G
    Minerva Endocrinol; 1990; 15(1):29-36. PubMed ID: 2274011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
    Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
    BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R; Ruchała M; Sawicka J; Kotwicka M; Liebert W; Sowiński J
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.
    Bandgar TR; Sarathi V; Shivane V; Bansode N; Menon PS; Shah NS
    J Postgrad Med; 2010; 56(1):7-11. PubMed ID: 20393242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogs in the treatment of acromegaly.
    Lamberts SW; Reubi JC; Krenning EP
    Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pasireotide in Acromegaly: A Review.
    McKeage K
    Drugs; 2015 Jun; 75(9):1039-48. PubMed ID: 26017304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide for acromegaly treatment: a reappraisal.
    Giustina A; Karamouzis I; Patelli I; Mazziotti G
    Expert Opin Pharmacother; 2013 Dec; 14(17):2433-47. PubMed ID: 24124691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin agonists for treatment of acromegaly.
    Ben-Shlomo A; Melmed S
    Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin analogs in acromegaly.
    Freda PU
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
    [No Abstract]   [Full Text] [Related]  

  • 20. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.